Genetic imbalances revealed by comparative genomic hybridization in Ewing tumors - PubMed

Affiliations

• PMID: 11550284
• DOI: 10.1002/gcc.1178

Comparative Study

Genetic imbalances revealed by comparative genomic hybridization in Ewing tumors

T Ozaki et al. Genes Chromosomes Cancer. 2001 Oct.

Abstract

Ewing tumors are characterized by reciprocal translocations involving the EWS gene on 22q12 fused to ETS transcription-factor family members. Little is known about further aberrations contributing to tumor development and progression. Sixty-two frozen tumors with known EWS rearrangements (52 primary tumors, 10 relapses) of ET patients registered in the EICESS protocol were analyzed by comparative genomic hybridization (CGH). The median number of changes in 52 primary and 10 relapsed cases was 2.5 and 5.0 per tumor (P = 0.153). Frequent abnormalities included gains of chromosomes 8, 12, 20, and 1q and losses of 16q and 19q. Neither number nor type of aberration was associated with histology, tumor size, disease stage, tumor localization, or histologic tumor response to chemotherapy. Among the 52 primary tumors, 26 with Type I fusion (EWS exon 7 to FLI1 exon 6) and 26 with other fusion types had a median of 2.0 and 3.0 aberrations per tumor, respectively (P = 0.031). Combinations of gains of chromosomes 8 and 12, gains of chromosome 20, and either gains of 8q or 18q and losses of 16q and 17p frequently occurred. The cumulative overall survival (OAS) was different between 35 patients with <5 aberrations and 13 patients with > or =5 aberrations (P = 0.009). Univariate analysis showed that patients with gains of 1q, 2q, 12, and 20 or losses of 16q and 17p had significantly lower OAS than those without aberrations. By multivariate analysis, loss of 16q (relative risk [RR] = 5.3; P = 0.0006) was an independent prognostic factor.

Similar articles

• Genetic imbalances revealed by comparative genomic hybridization in osteosarcomas.

  Ozaki T, Schaefer KL, Wai D, Buerger H, Flege S, Lindner N, Kevric M, Diallo R, Bankfalvi A, Brinkschmidt C, Juergens H, Winkelmann W, Dockhorn-Dworniczak B, Bielack SS, Poremba C. Ozaki T, et al. Int J Cancer. 2002 Dec 1;102(4):355-65. doi: 10.1002/ijc.10709. Int J Cancer. 2002. PMID: 12402305

• Population-based genetic alterations in Ewing's tumors from Japanese and European Caucasian patients.

  Ozaki T, Schaefer KL, Wai D, Yokoyama R, Ahrens S, Diallo R, Hasegawa T, Shimoda T, Hirohashi S, Kawai A, Naito N, Morimoto Y, Inoue H, Boecker W, Juergens H, Winkelmann W, Dockhorn-Dworniczak B, Poremba C. Ozaki T, et al. Ann Oncol. 2002 Oct;13(10):1656-64. doi: 10.1093/annonc/mdf218. Ann Oncol. 2002. PMID: 12377657

• Genomic aberrations in carcinomas of the uterine corpus.

  Micci F, Teixeira MR, Haugom L, Kristensen G, Abeler VM, Heim S. Micci F, et al. Genes Chromosomes Cancer. 2004 Jul;40(3):229-46. doi: 10.1002/gcc.20038. Genes Chromosomes Cancer. 2004. PMID: 15139002

• CGH analysis of secondary genetic changes in Ewing tumors: correlation with metastatic disease in a series of 43 cases.

  Brisset S, Schleiermacher G, Peter M, Mairal A, Oberlin O, Delattre O, Aurias A. Brisset S, et al. Cancer Genet Cytogenet. 2001 Oct 1;130(1):57-61. doi: 10.1016/s0165-4608(01)00454-x. Cancer Genet Cytogenet. 2001. PMID: 11672775 Review.

• Molecular confirmation of Ewing sarcoma.

  Dagher R, Pham TA, Sorbara L, Kumar S, Long L, Bernstein D, Mackall C, Raffeld M, Tsokos M, Helman L. Dagher R, et al. J Pediatr Hematol Oncol. 2001 May;23(4):221-4. doi: 10.1097/00043426-200105000-00009. J Pediatr Hematol Oncol. 2001. PMID: 11846300 Review.

Cited by

• Ependymoma in children: molecular considerations and therapeutic insights.

  Kim JH, Huang Y, Griffin AS, Rajappa P, Greenfield JP. Kim JH, et al. Clin Transl Oncol. 2013 Oct;15(10):759-65. doi: 10.1007/s12094-013-1041-1. Epub 2013 Apr 25. Clin Transl Oncol. 2013. PMID: 23615979 Review.

• MDM2 amplification and fusion gene ss18-ssx in a poorly differentiated synovial sarcoma: A rare but puzzling conjunction.

  Di Mauro I, Mescam-Mancini L, Chetaille B, Lae M, Pierron G, Dadone-Montaudie B, Bazin A, Bouvier C, Michiels JF, Pedeutour F. Di Mauro I, et al. Neoplasia. 2020 Aug;22(8):311-321. doi: 10.1016/j.neo.2020.05.003. Epub 2020 Jun 16. Neoplasia. 2020. PMID: 32559641 Free PMC article.

• Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma.

  Jahromi MS, Putnam AR, Druzgal C, Wright J, Spraker-Perlman H, Kinsey M, Zhou H, Boucher KM, Randall RL, Jones KB, Lucas D, Rosenberg A, Thomas D, Lessnick SL, Schiffman JD. Jahromi MS, et al. Cancer Genet. 2012 Jul-Aug;205(7-8):391-404. doi: 10.1016/j.cancergen.2012.05.012. Cancer Genet. 2012. PMID: 22868000 Free PMC article.

• Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children's Oncology Group.

  Shukla N, Schiffman J, Reed D, Davis IJ, Womer RB, Lessnick SL, Lawlor ER; COG Ewing Sarcoma Biology Committee. Shukla N, et al. Front Oncol. 2013 Jun 6;3:141. doi: 10.3389/fonc.2013.00141. eCollection 2013. Front Oncol. 2013. PMID: 23761859 Free PMC article.

• Microsatellite instability in Ewing tumor is not associated with loss of mismatch repair protein expression.

  Alldinger I, Schaefer KL, Goedde D, Ottaviano L, Dirksen U, Ranft A, Juergens H, Gabbert HE, Knoefel WT, Poremba C. Alldinger I, et al. J Cancer Res Clin Oncol. 2007 Oct;133(10):749-59. doi: 10.1007/s00432-007-0220-2. Epub 2007 May 25. J Cancer Res Clin Oncol. 2007. PMID: 17530287

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Wiley

• Medical

  • MedlinePlus Health Information